Technology | March 08, 2013

Boston Scientific Launches Rubicon Support Catheter in 0.035-inch and 0.018-inch Diameters

New tool available to assist in the treatment of peripheral arterial disease

March 8, 2013 — Boston Scientific Corporation has begun the launch of its 0.035-inch and 0.018-inch Rubicon Support Catheter in the United States. The device is designed to assist physicians with placement and support of guidewires that are used in peripheral vascular procedures to deliver stents and balloons to open blockages in the legs and other peripheral arteries. Boston Scientific is also launching the 0.035-inch Rubicon Support Catheter in Europe to build on the momentum of the 0.018-inch size that was introduced in that region last fall.

Peripheral arterial disease (PAD) affects approximately 27 million people worldwide.  It can cause pain or cramping in the legs and hips due to lack of blood supply while walking or climbing stairs. In some cases, the condition can become so severe it can lead to critical limb ischemia and the need for amputation. The Rubicon Support Catheter was designed to help clinicians more easily reach blockages.

"The Rubicon Support Catheter offers an outstanding combination of features," said Louis Lopez, M.D., St. Joseph's Hospital, Fort Wayne, Ind. "It offers the pushability, low-profile and flexibility needed for navigating through the types of challenging, complex lesions that physicians face in the peripheral vascular space."

The Rubicon Support Catheter had previously been available from Boston Scientific in a 0.014-inch diameter only, and by launching the 0.035 and 0.018-inch sizes, Boston Scientific now offers physicians a full range of diameters to treat patients with peripheral arterial disease. The Rubicon Support Catheter is also available in a variety of lengths including 65 cm, 90 cm, 135 cm and 150 cm.

"Support catheters can help physicians treat more patients by facilitating the crossing of complex lesions," said Jeff Mirviss, president, peripheral interventions, Boston Scientific. "By making a full range of diameters of Rubicon Support Catheters available, we are offering more choices to clinicians. The Rubicon Support Catheter is one of many new solutions that Boston Scientific has introduced to the market during the past two years and demonstrates our continued commitment to global leadership in peripheralpIntervention."

The Rubicon Support Catheter has received FDA 510(k) clearance and achieved CE mark status.

For more information: www.bostonscientific.com

Related Content

Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab | November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Overlay Init